COMPANY DATA

Source: Bloomberg

Company Description

INVESTMENT SUMMARY

• Trading on fair value on absolute and relative basis of FY20e of 35.7x, ~1.6% dividend yield.
• Attractive hearing loss market with (1) ~5% of world’s population or 360m have disabling hearing loss (328m adults and 32m children); (2) 1 in 3 people over age of 65 affected by hearing loss; (3) less than 5% market penetration.
• Market leading positions globally.
• Direct-to-consumer marketing expected to fast track market growth.
• Best in class R&D program (significant dollar amount) leading to continual development of new products and upgrades to existing suite of products.
• New product launches driving continued demand in all segments.
• Attractive exposure to growth in China, India and more recently Japan.
• Solid balance sheet position.

• Product recall.
• R&D program fails to deliver innovative products.
• Increase in competitive pressures.
• Change in government reimbursement policy.
• Adverse movements in AUD/USD.
• Emerging market does not recoup – significant downside to earnings.

Figure 1: COH Revenue by Segment

Source: Company

Figure 2: COH Revenue by Region

Source: Company

• Strong FY19 guidance and outlook. On the analyst call, management pointed out “for FY19, COH expects to deliver reported net profit of $265-275m, an 8-12% increase on FY18”. COH is “targeting to maintain the net profit margin”. COH has “a number of large long-term investment projects including the development of our China manufacturing facility, with the construction phase expected to be complete by the end of FY20, and investments in IT platforms to strengthen our connected health, digital and cyber security capabilities. These projects are expected to increase capital expenditure levels to $80-100m per annum over the next few years”. Management continues “to target a dividend payout ratio of around 70% of net profit”.
• Cochlear implants (62% of revenue) – strong performance driven by sales in emerging markets. The segment saw revenues grew 8% (8% in CC) with unit growth of 8% (up 11% excluding the impact of Chinese Central Government tender units; FY18 result included ~1,100 Chinese Central Government tender units compared to ~1,900 in FY17.). Reported average selling prices were stable in constant currency but there was some price pressure in some markets, particularly Western Europe. Across the developed world (80% of revenues), sales of units grew by +9%, especially driven by sales in US and UK. The Nucleus 7 Sound Processor (a world’s first which is specifically made for iPhone cochlear implant sound processor), was launched in 2Q and drove market share gains for COH. In emerging markets, sales of units grew by over 15% (adjusted for the impact of lower Chinese Central Government tender units), especially in the Middle East and the China private pay market.
• Services (sound processor upgrades and other) (26% of revenue) – performed strongly. The segment saw revenue increase by 16% (15% in CC) driven by 1. Release of the Nucleus 7 Sound Processor during the 2Q18; and 2. First full year of revenue from Sycle (audiology practice management software business acquired by COH in May 2017).
• Acoustics (bone conduction and acoustic implants) (12% of revenue) – the negative of the result following a strong FY17 result. Revenue declined by 1% (0% in CC), following a strong 26% growth in CC in FY17. According to management, they are seeing solid demand for the Baha 5 sound processor range.

COH FY18 FINANCIAL RESULTS…

Figure 3: Results Summary

Source: Company

Source: Company

Source: BTIG, Company, Bloomberg

COMPANY DESCRIPTION

Cochlear Ltd (COH) researches, develops and markets cochlear implant systems for hearing impaired people. COH’s hearing implant systems include Nucleus and Baha and are sold globally. COH has direct operations in 20 countries and 2,800 employees.